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ABSTRACT 
Objective: A stability indicating RP-HPLC method was developed and validated for the determination of Valsartan using Telmisartan (10 µg/ml) as 
the internal standard.  
Methods: In this procedure Phenomenex ODS C-18(250×4.6 mm, packed with 5 micron) column was used with a new mobile phase consisting of 
methanol: acetonitrile: water (70:15:15 v/v) and the pH was adjusted to 3 by 0.1% glacial acetic acid with a flow rate of 1 ml/min. The eluents were 
monitored at 249 nm. Valsartan was subjected to stress conditions including hydrolytic degradation in acidic, basic and neutral conditions, 
oxidation, photolytic, UV degradation and thermal degradation.  
Results: Linearity was obtained in the concentration range of 10-90 µg/ml (R2
Conclusion: The method was validated for accuracy, precision, linearity, specificity and robustness and revealed that it is specific, accurate, rapid, 
precise, reliable and reproducible enough to analyze commercial dosage forms as per ICH guidelines.  
 =0.999) and with a regression equation y=0.074x+0.005. The LOD 
and LOQ values were 0.261 and 0.791 µg/ml respectively. The drug had shown promising degradation in the acidic, basic, neutral, thermal and 
oxidative stress conditions.  
Keywords: Valsartan, Stability Studies, Stability Indicating RP-HPLC, Stress Degradation, ICH Guidelines. 
 
INTRODUCTION 
Valsartan is chemically 3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-
5-yl) phenyl] phenyl]methyl]amino]-butanoic acid (fig. 1)[1], 
Angiotensin II receptor antagonist, acting on the AT1 subtype &used 
for treatment of high blood pressure, of congestive heart failure 
(CHF), and post-myocardial infarction (MI). By blocking the action of 
Angiotensin, Valsartan dilates blood vessels and reduces blood 
pressure [2]. The focus of the present study was to develop & 
validated a rapid, stable, & economic stability indicating HPLC 
method for the estimation of Valsartan in bulk and tablet dosage 
forms. As per ICH Q1A (R2) guidelines the purpose of stability 
testing is to provide evidence on how the quality of a drug substance 
or drug product varies with time under the influence of a variety of 
environmental factors, such as temperature, humidity, and light, and 
to establish a retest period for the drug substance or a shelf life for 
the drug product and recommended storage conditions.  
 
 
Fig. 1: Chemical structure of valsartan 
 
From the literature survey [3-10] it has been found that many HPLC 
methods are available for the determination of valsartanin bulk as 
well as in formulations along with stability indications. But with the 
use of this new mobile phase i.e. methanol: acetonitrile: water 
(70:15:15 v/v) pH adjusted to 3 by glacial acetic acid, the detection 
of degradant peaks of UV, Oxidative and Thermal stresses was found 
to be better and precise. It has also been found that using the new 
mobile phase, the developed RP HPLC method became more robust, 
accurate and highly précised. As the separation of the degradants 
using this mobile phase is quite good, isolation of the degradants 
with preparative techniques can also be achieved using this mobile 
phase. Further LC MS-MS analysis will help to deduce the structures 
of the degradants which can help to establish the possible 
degradation pathway of this drug. So this method can be 
economically very useful in both research and industrial aspect. 
MATERIALS AND METHODS 
Chemicals and reagents 
Valsartan API was purchased from Cadila Healthcare Ltd, 
Ahmedabad, India. The HPLC grade solvents used were obtained 
from Merck (India) Ltd, Mumbai. HPLC grade water was prepared 
using Millipore System (Millipore, Molesheim France, and Model 
Elix-10). All other reagents were of HPLC grade. 
Equipments 
HPLC was performed on Shimadzu HPLC with LC-20AT pumps 
besides SPD-20A UV-Visible detector. Shimadzu spin crom-CFR 
software was used along with Phenomenex ODS C-18(250×4.6 mm, 
packed with 5 microns) for the separation. 
Chromatographic conditions 
Selected drug was injected to the column with different mobile 
phases of different ratios with different flow rates till sharp peaks 
without any interference peaks containing spectra were obtained. 
Final mobile phase was chosen as methanol: water: acetonitrile 
(70:15:15) and pH was adjusted to 3 with 0.1 N glacial acetic acid. 
The mobile phase was then sonicated for 10 minutes and filtered 
through 0.45μ membrane filter. C-18 column was equilibrated with 
the mobile phase. Mobile phase flow rate was maintained at 1 
ml/min and eluent were monitored at 249 nm wavelength. The 
samples were injected using a 20 μl fixed loop. All determinations 
were performed at ambient temperature for a run time of 6 min. 
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Preparation of stock and working solutions 
About 50 mg of valsartan was weighed accurately and was taken in 
50 ml volumetric flasks. It was dissolved in the mobile phase and the 
volume was made up to the mark to prepare the 1000 µg/ml stock 
solution. From the above prepared stock solution of valsartan 5 ml 
was pipette out in to a 50 ml volumetric flask and the volume was 
made to up to the mark with mobile phase to yield the 100 µg/ml 
working solution of valsartan. 
About 50 mg of telmisartan was weighed accurately and was taken 
in a 50 ml volumetric flask. It was dissolved in the mobile phase and 
the volume was made up to the mark to make a stock solution of 
1000 µg/ml. From this stock, 5 ml was pipette out and diluted to 50 
ml with the mobile phase to yield the working solution of 
Telmisartan (100 µg/ml). 
Method validation 
Validation of the established HPLC method was done as per the ICH 
guidelines to assess the accuracy, precision, specificity, ruggedness, 
robustness, LOD and LOQ values. The accuracy of the method was 
determined by calculating recoveries of drug by the method of 
standard drug. Known amounts of standard drug corresponding to 
80%, 100% and 120% of the label claim was added to pre quantified 
sample solution and the amounts of drug were estimated by 
measuring the peak areas and by fitting these values to the straight 
line equation of calibration curve. The intraday and inter-day 
precision studies of the drugs were carried out by estimating the 
corresponding responses on the same day and consecutive three 
days respectively.  
The results were reported in terms of standard deviation and % 
RSD. The specificity of the proposed RP-HPLC method was 
determined by complete separation of two peaks with parameters 
like retention time (Rt), resolution (RS) and tailing factor (T). 
Robustness of the method was studied by deliberate variations of 
the analytical parameters such as flow rate (1±0.2 ml/min), 
concentration of methanol (90±2%). Ruggedness is the degree of 
reproducibility of the results obtained under a variety of conditions, 
expressed as %RSD. These conditions include different laboratory 
conditions and different analysts. 
Forced degradation studies 
The force degradation studies were conducted on the sample using 
acid, alkaline, oxidative, thermal, and photolytic and UV 
degradations. Neutral stress was given by dissolving 10 mg of drug 
into 10 ml of methanol followed by volume made up with water and 
refluxing for 6 h. Acidic and basic stresses were given by using 0.1 N. 
0.5 N and 1 N of hydrochloric acid and sodium hydroxide followed 
by 6 h reflux. Oxidative stress was put on by using 1 % w/v, 2 % and 
3 % w/v hydrogen peroxide. Photo degradation was done upon 
exposure to sunlight for 12,24,72 h. UV illumination of 1.2×106
Percentage recovery was calculated from differences between the 
peak areas obtained for fortified and unfortified solutions.  
lux h 
for 12,24,72 h was used as the stress factor for UV degradation. 
Thermal degradation was carried out at 70 °C dry heat for 10, 20 
and 30 days.  
RESULTS  
As shown from the data in table 1, good recoveries were made at 
each added concentration, confirming that the method was accurate. 
Data obtained from analysis of the samples on the same day (n = 6) 
and on consecutive days (n = 6) are given in table 1. As the % RSD 
values of the data obtained were well below 2%, thereby the values 
indicate that the method was sufficiently precise.  
Linear calibration plots of each drug for the previously mentioned 
method were obtained over the calibration ranges 10–90 µg/ml; the 
correlation coefficient obtained was 0.999 (fig. 3). The 
chromatogram is shown in fig. 2. The results show that the good 
correlation existed between the peak area and concentration of the 
analyte. The LOD and LOQ values found for the analysis were 0.261 
and 0.791 µg/ml respectively.  
Robustness study was being performed by changing two parameter 
pH and flow rate. pH had been altered to 2.8 and 3.2 whereas flow 
rate was changed to 0.8 an 1.2. Ruggedness of the established 
method was assessed by performing 6 different injections of a 
particular concentration of the drug by two different analysts. 
Results obtained (shown in table 1-5) and % RSD values calculated 
clearly illustrate the ruggedness of the method. 
 
 




Fig. 3: Calibration curve of valsartan
 
Table 1: Accuracy data of the method 
Samples Concentration (μg/ml) % Recovery Statistical Analysis 
Amount present in Formulation Amount of drug added 
S1: 80% 30 24 100.02 Mean=99.88 
SD=0.169 
% RSD=0.168 
S2: 80% 30 24 99.89 
S3: 80% 30 24 99.75 
S4: 100% 30 30 100.07 Mean=99.94 
SD=0.132 
% RSD=0.132 
S5: 100% 30 30 99.79 
S6: 100% 30 30 99.98 
S7: 120% 30 36 99.59 Mean=99.78 
SD=0.194 
% RSD=0.193 
S8: 120% 30 36 99.73 
S9: 120% 30 36 100.04 
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Table 2: Intraday precision data 
S. No. Concentration (μg/ml) Peak Area Ratio Calc. Amt. (μg/ml) Statistical Analysis 




2 30 2.209 29.91 
3 30 2.228 30.17 
4 30 2.207 29.89 
5 30 2.219 30.05 
6 30 2.212 29.95 
 
Table 3: Inter-day precision data 
S. No. Concentration 
(μg/ml) 
Day 1 Day 2 Day 3 Statistical analysis 




2 30 2.237 2.229 2.241 
3 30 2.205 2.208 2.201 
4 30 2.217 2.227 2.205 
5 30 2.211 2.206 2.209 
6 30 2.225 2.239 2.245 
Mean Peak Area Ratio 2.221 2.224 2.222 
Calc. Amt. (μg/ml) 30.08 30.12 30.09 
 
Table 4: Robustness data 
pH 2.8 pH 3.2 
Conc. (μg/ml) Peak Area Ratio Calc. 
Amt. 
(μg/ml) 
Statistical Analysis Conc. (μg/ml) Peak Area Ratio Calc. Amt. 
(μg/ml) 
Statistical Analysis 









30 2.218 30.04 30 2.229 30.18 
30 2.211 29.94 30 2.233 30.24 
30 2.226 30.14 30 2.203 29.83 
30 2.207 29.89 30 2.214 29.98 
30 2.219 30.05 30 2.236 30.28 
 
Table 5: Ruggedness data 
Analyst-1 Analyst-2 
Conc. (μg/ml) Peak Area Ratio Calc. Amt. 
(μg/ml) 
Statistical Analysis Conc. (μg/ml) Peak Area Ratio Calc. Amt. 
(μg/ml) 
Statistical Analysis 









30 2.232 30.22 30 2.237 30.29 
30 2.230 30.20 30 2.238 30.31 
30 2.209 29.91 30 2.227 30.16 
30 2.204 29.85 30 2.201 29.81 
30 2.235 30.27 30 2.243 30.37 
In case of acidic, neutral, basic, photo, UV and thermal stress 100 µg/ml solutions were made and injected into the system. For oxidative stress, 60 
µg/ml solutions was made and injected. The chromatograms of the drug and degradants under different stress conditions are given in the fig. 4. 
Individual degradation study results are elaborated from table 6-12 and overall summary of the results of the degradation study is given in table 13. 
 
Table 6: Hydrolytic degradation in neutral condition of valsartan 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 




2 2.173 68.824 4.843 2.5 2.5 0.16 
3 2.863 83.632 3.474 3.7 1.8 0.42 
4 3.637 32.965 1.598 1.1 0.8 0.27 
5 3.937 1614.188 154.788 79.4 80.3 0.16 
6 4.870 95.254 3.020 3.3 1.6 0.29 
Total 2175.256 192.879 100 100 - 
 
Table 7: Degradation in acidic condition 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 




2 4.393 281.473 17.391 18.4 14.1 0.17 
Total 1826.246 157.74 100 100 - 
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Fig. 4: Degradation chromatograms under different stress conditions 
 
Table 8: Degradation in basic condition 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 
1 2.633 368.736 41.639 16.5 18.3 0.15 Drug Remaining= 
74.16 μg/ml 
%Degradation=25.84 
2 3.603 35.599 1.663 1.3 0.7 0.45 
3 3.953 1396.637 127.092 74.2 74.7 0.16 
4 4.920 169.072 10.427 8.0 6.3 0.20 
Total 1907.044 180.821 100 100 - 
 
Table 9: Thermal degradation 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 





2 2.833 11.999 1.120 0.5 0.5 0.24 
3 3.423 1.760 0.279 0.1 0.1 0.11 
4 3.663 1359.045 159.154 72.14 71.6 0.13 
5 4.933 567.501 49.941 25.66 26.0 0.16 
Total 2001.941 214.827 100 100 - 
 
Table 10: Oxidative degradation 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 




2 2.473 34.131 3.271 0.8 0.8 0.19 
3 2.733 2175.281 214.507 53.8 50.1 0.16 
4 3.153 261.389 16.908 5.8 4.1 0.29 
5 3.397 132.315 15.605 3.0 3.8 0.16 
6 3.550 130.210 14.824 2.9 3.6 0.15 
7 3.683 170.121 15.579 3.8 3.8 0.22 
8 3.973 944.861 80.041 22.0 21.8 0.16 
9 4.943 380.859 31.115 5.7 8.8 0.18 
Total 4325.406 405.126 100 100 - 
 
Table 11: Photolytic degradation 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 





2 2.463 7.106 0.629 0.4 0.3 0.18 
3 2.847 5.013 0.604 0.3 0.3 0.15 
4 3.207 38.440 2.696 2.0 1.3 0.15 
5 3.693 7.383 0.728 0.4 0.4 0.17 
6 4.033 1768.837 191.886 95.3 96.5 0.14 
7 5.010 10.525 0.846 0.6 0.4 0.20 
Total 1859.154 199.136 100 100 - 
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Table 12: UV degradation 
S. No. Reten. Time (min) Area (Mv. s) Height (Mv) Area (%) Height (%) W05 (min) Results 





2 2.463 3.414 0.468 0.2 0.2 0.12 
3 2.847 8.294 0.868 0.4 0.4 0.18 
4 3.210 46.247 3.349 2.3 1.5 0.14 
5 3.700 11.733 1.162 0.6 0.5 0.17 
6 4.030 1848.488 206.241 93.7 95.0 0.13 
7 5.007 30.627 2.713 1.5 1.3 0.17 
Total 1973.657 217.016 100 100 - 
 
Table 13: Overall summary of degradation study 
Stress condition Stressing agents Time (h) Degradation 
Neutral WATER 6  14.15% 
Acidic 
 
0.1 N 6  Stable 
0.5 N 6  Stable 
1 N 6  17.88% 
Basic 0.1 N 6  Stable 
0.5 N 6  Stable 
1 N 6  25.84% 
Oxidation 1% H2O 6  2 Stable 
2% H2O 6  2 Stable 
3% H2O 6  2 16.86% 
Light SUN LIGHT 12  Stable 
24  Stable 
72  5.84% 
Thermal 70 °C HEAT 240  Stable 
480  Stable 
720  27.86% 
UV Radiation 1.2×106 12   lux h (UV illumination at 256 nm) Stable 
24  Stable 
72  1.56% 
 
DISCUSSION 
The developed RP-HPLC stability indicating assay method was found 
suitable for the analysis of drug in their pure form in presence of 
their respective degradants since the resolution between the drugs 
with its corresponding degradants was better. ADVANTAGE: 
Previously reported methods for analysis of valsartan in bulk are 
having retention times more than 4 minutes whereas in this method 
it is less than 4 minutes. More to that 99.94% accuracy and huge 
linearity range of 10-90 µg/ml with such a low LOD and LOQ values 
i.e. 0.261 and 0.791 µg/ml was not reported in earlier methods. 
Previously linearity was assessed in between 16-320 µg/ml range 
and LOD and LOQ values were also more than 10 µg/ml. The 
sensitivity and accuracy of the method were also ascertained by 
using internal standard telmisartan which is not reported earlier. 
With the use of the newly developed mobile phase and internal 
standard, further bio-analytical method can be developed. 
CONCLUSION: The results of stability studies of valsartan suggest 
that the drug is more prone to thermolytic, hydrolytic and oxidative 
degradations. So measures should be focused to reduce the exposure 
of valsartan to atmospheric conditions. 
ACKNOWLEDGEMENT 
Authors are thankful to Director cum Principal of Royal College of 
Pharmacy and Health Sciences, Berhampur, Odisha-76002 for 
providing the necessary facilities for this research work.  
CONFLICT OF INTERESTS 
Declared None. 
REFERENCES 
1. Blake PS. Cardiovascular drugs. In: Brayfield; Alison. editors. 
Martindale the complete drug reference. 33rd ed. London: 
Pharmaceutical Press; 2002. p. 853. 
2. Tripathi KD. Essentials of medical pharmacology. New Delhi: 
Jaypee Brothers Medical Publishers; 2008. p. 875. 
3. Krishnaiah C, Reddy AR, Kumar R, Mukkanti K. Stability-
indicating UPLC method for determination of Valsartan and their 
degradation products in active pharmaceutical ingredient and 
pharmaceutical dosage forms. J Pharm Biomed Anal 
2010;53(3):483–9.  
4. Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R. 
Development and validation of a method for quantitative 
determination of valsartan in human plasma by liquid 
chromatography-tandem mass spectrometry. J Pharm Biomed 
Anal 2007;43:1769–74. 
5. Rizzo M, Ventrice D, Casale F, Caselli GF, Makovec F. 
Pharmacokinetic study of a new angiotensin-AT1 antagonist by 
HPLC. J Pharm Biomed Anal 2008;48:422–7. 
6. Shah NJ, Suhagia BN, Shah RR, Patel NM. Development and 
validation of HPTLC method for the simultaneous estimation of 
Valsartan and hydrochlorothiazide in tablet dosage form. 
Indian J Pharm Sci 2009;71(1):72–4. 
7. Uttamrao KS, Bhatia MS. Validation of Valsartan and its 
degradation products by HPLC. J Chem Metrol 2010;3(1):1-12. 
8. Chitlange SS, Bagri K, Sakarkar DM. Stability indicating RP-HPLC 
method for simultaneous estimation of Valsartan and 
Amlodipine in capsule formulation. Asian J Res Chem 
2008;1(1):15-8. 
9. Daneshtalab N. High-performance liquid chromatographic 
analysis of angiotensin II receptor antagonist valsartan using a 
liquid extraction method. J Chromatogr B 2002;76(6):345–9. 
10. Sibel A, Ozakan SE, Gorger N, Altinay S, Zuhre S. Simultaneous 
determination of valsartan and hydrochlorthiazide in tablets by 
first-derivative UV spectrophotometry and LC. J Pharm Biomed 
Anal 2001;25(5):1009-13. 
 
